产品说明
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
生化/生理作用
Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-Deoxy-5-fluorocytidine (5′-DFCR) and 5′-Deoxy-5-fluorouridine (5′-DFUR), to form 5-fluorouracil.
包装
Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia
其他说明
Sales restrictions may apply.
基本信息
| 经验(实验)分子式 | C15H22FN3O6 |
| 分子量 | 359.35 |
| MDL编号 | MFCD00930626 |
产品性质
| 质量水平 | 100 |
| manufacturer/tradename | BP |
| 储存温度 | 2-8℃ |
| SMILES string | O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C |
| InChI | 1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 |
| InChI key | GAGWJHPBXLXJQN-UORFTKCHSA-N |
| Gene Information | human ... TYMS(7298) |
安全信息
| 象形图 |  |
| 警示用语： | Danger |
| 危险声明 | H341 - H350 - H360FD |
| 预防措施声明 | P201 - P308 + P313 |
| 危险分类 | Carc. 1B - Muta. 2 - Repr. 1B |
| 储存分类代码 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
| 闪点(F) | Not applicable |
| 闪点(C) | Not applicable |
m.cnreagent.com
